Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary

product characteristics. 3.1.4 The cost of abciximab is £280 (net) for a 10-mg vial (BNF 43rd edition). For a 70-kg person, the cost per course ranges from £840 to £1,120, depending on the duration of treatment (costs rounded to full vials). 3.2 Eptifibatide (Integrilin) 3.2.1 Eptifibatide is a synthetic cyclic heptapeptide and is 1 of the small-molecule GP IIb/IIIa inhibitors. It reversibly inhibits platelet aggregation by preventing the binding of fibrinogen and other adhesive ligands to the GP IIb/IIIa receptor. 3.2.2 Eptifibatide is indicated for the prevention of early MI in patients presenting with unstable angina or non-Q-wave MI (NSTEMI) who have had chest pain within the last 24 hours and who have electrocardiogram (ECG) changes and/or elevated cardiac enzymes. It is administered intravenously at an initial bolus dose of 180 microgram/kg followed by a maintenance dose of 2.0 microgram/kg/min for up to 72 hours (up to 96 hours if the patient has a PCI during treatment). 3.2.3 As with the other GP IIb/IIIa inhibitors, the side effects of eptifibatide (including bleeding and thrombocytopenia) are related to its pharmacological effects. For full details of side effects and contraindications, see the summary of product characteristics. 3.2.4 The cost of eptifibatide is
